UroGen Pharma (NASDAQ:URGN) Trading Up 10.8% - Here's What Happened

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) shares were up 10.8% on Monday . The company traded as high as $11.49 and last traded at $10.94. Approximately 193,895 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 415,814 shares. The stock had previously closed at $9.87.

Wall Street Analysts Forecast Growth

URGN has been the subject of several research reports. The Goldman Sachs Group lowered their price objective on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Scotiabank assumed coverage on UroGen Pharma in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of UroGen Pharma in a report on Monday. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price on the stock. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Monday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, UroGen Pharma has an average rating of "Buy" and an average price target of $32.86.

UroGen Pharma Trading Up 8.9 %

The company has a market cap of $495.28 million, a P/E ratio of -3.43 and a beta of 0.80. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The business has a 50 day moving average price of $10.43 and a 200-day moving average price of $11.09.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to analysts' expectations of $25.25 million. Analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Insider Activity at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company's stock, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

Several large investors have recently modified their holdings of the stock. RTW Investments LP raised its holdings in UroGen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock valued at $40,841,000 after acquiring an additional 47,447 shares during the period. Toronto Dominion Bank acquired a new stake in UroGen Pharma during the 4th quarter worth approximately $18,628,000. Vestal Point Capital LP boosted its stake in UroGen Pharma by 307.5% in the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock valued at $17,360,000 after purchasing an additional 1,230,000 shares during the period. Acorn Capital Advisors LLC bought a new stake in UroGen Pharma in the 4th quarter valued at $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in UroGen Pharma by 2.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company's stock valued at $14,667,000 after buying an additional 36,084 shares in the last quarter. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.